Metabolic relationships of bisphosphonate-induced osteonecrosis of the jaw: review
DOI:
https://doi.org/10.59334/ROV.v2i29.144Keywords:
Bisphosphonates, osteonecrosis of the jaw, antiresorptive, antiangiogenicAbstract
Bifosphonates are antiresorptive drugs of choice in the treatment of a wide range of osteolytic pathologies, such as osteoporosis, Piaget’s disease, hypercalcemia associated with bone metastasis and bone lesions due to multiple myeloma, among others (Adober et ál., 2000). The orally use of these drugs reports adverse effects in the digestive tract: nausea, abdominal pain, heartburn, ulcers and esophageal stenosis (Jódar et ál., 2002). Since 2003, they have also been associated with a bone exposure in the maxilla called bisphosphonate-induced osteonecrosis of jaws; particularly in intravenous application with greater bioavailability (Marx et ál., 2003).
In patients who consume BFs aggressive dental treatments can trigger osteonecrosis of the jaw (Barquero, 2016). The present review focuses on mechanisms of action of BFs that justify their therapeutic action and adverse effects, among them the development of osteonecrosis of jaw; also seeks to It also aims to draw attention to the need to establish dental protocols for patients who are treated with BFs for long periods.
Downloads
References
Adober, R. et ál, (2000). Revisión clínica de la utilización de los bifosfonatos. Farm Hosp. 24(2):74-82. Disponible en https://www.sefh.es/revistas/vol24/n2/240203.pdf.
Arrabal M. et ál. (2007). Tratamiento de la litiasis renal con bifosfonatos. Arch. Esp, Urol. 60(7):745-754. https://doi.org/10.4321/S0004-06142007000700004
Assael, L.A. (2009). Oral bisphosphonates as a cause of biphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg. 67:35-43. https://doi.org/10.1016/j.joms.2009.01.003
Barquero, I. (2016). Osteonecrosis de los maxilares inducida por bifosfonatos. Odontología Vital 25:5-8.
Barret, J.; Worth, E.; Bauss, F. & Epstein, S. (2004). Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 44: 951-965. https://doi.org/10.1177/0091270004267594
Baynes, D.J. N. y Dominiczak, M. (2015). Bioquímica médica. Cuarta edición. Pp.343-345 y 582-583. Elsevier Saunders. España.
Birkett J. (2005). Farmacocinética fácil. McGraw Hill Interamericana de España.
Borgioli, A. et ál. (2009). Bisphosphonates-related osteonecrosis of the jaw: clinical and physiopathological considerations. Ther Clin Risk Manag. 5:217-227. https://doi.org/10.2147/TCRM.S1697
Borissoff, J.I. et ál. (2011). The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 364(18):1746-1760. https://doi.org/10.1056/NEJMra1011670
Buckley, K.A. & Fraser W.D. (2002). Receptor activator for nuclear factor kappa B ligand and osteoprotegrin regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markes. Ann Clin Biochem.39:551-556. https://doi.org/10.1177/000456320203900602
Cremers, S. & Papapoulos, S. (2011). Pharmacology of the bisphosphonates. Bone. 49:42-49. https://doi.org/10.1016/j.bone.2011.01.014
Doménech J. et ál. Editores (2013). Tratado general de Biofarmacia y Farmacocinética. Vol. I. LADME. Análisis farmacocinético. Biodisponibilidad y bioequivalencia. Editorial Síntesis. España.
Fraga, A. et ál. (2009). Hipoxia Tumoral. Papel del factor inducible por hipoxia. Actas Urol Esp. Vol. 33. No. 9. Disponible en http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0210-48062009000900003 .
Fraser, W.D. (2009). Hyperparathyroidism. Lancet. 374:145-158. https://doi.org/10.1016/S0140-6736(09)60507-9
García-Ferrer, L. et ál. (2008). MRI of mandibular osteonecrosis secondary to bisphosphonates. Am J Roent-genol. 190:949-955. https://doi.org/10.2214/AJR.07.3045
Gómez F. R. et ál. (2008). Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal. 13:318-324.
Grunewald, M. et ál. (2006). VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 124(1):175-189. https://doi.org/10.1016/j.cell.2005.10.036
Harada, S. & Rodan, G.A. (2003). Control of osteoblast function and regulation of bone mass. Nature. 423:349-355. Hass, E.M. et ál. (2003). Adult intussusceptions. Am J Surg. 186:75-76. https://doi.org/10.1038/nature01660
Jódar, E.; Martínez, D. y Segarra, M.C. (2002). Efectos adversos y contraindicaciones de los bifosfonatos. En: Rapado, A. y Díaz Curiel, M. (ed.), Bifosfonatos en las enfermedades del metabolismo óseo y mineral. Fundación Hispana de Osteoporosis y Enfermedades Metabólicas. FHOEMO.
Laplante, M. & Sabatini, D.M. (2012). mTOR signaling in growth control and disease. Cell. 149: 274-293. https://doi.org/10.1016/j.cell.2012.03.017
Lavandeira, H. et ál. (2007). Un nuevo alerta rojo en odontología: la administración de bifosfonatos. Rev Asoc Odontol Argent. 95:331-334.
Lieberman, M. Marks, A.D. & Peet, A. (2013). Bioquímica médica básica: un enfoque clínico. 4ta ed. Lippincott Williams & Wilkins.
Lin, J.H. (1996). Bisphosphonates: a review of their pharmacokinetic properties. Bone. 18:75-85. https://doi.org/10.1016/8756-3282(95)00445-9
Lomashvili, K. A. et ál. (2008). Regulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcification. Kidney Int. 73: 1024-1030. https://doi.org/10.1038/ki.2008.26
Marx, R.E. et ál. (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61(10): 1115-1117. https://doi.org/10.1016/S0278-2391(03)00720-1
Mish, C.E. (2009). Implantología contemporánea. 3ra. Edición. Elsevier. Cap. 6. Pp. 71-90. Barcelona. España.
Morag, Y. et ál. (2009). Bisphosphonate related osteonecrosis of the jaw: a pictorial review. Radiographics. 29:1971-1986. https://doi.org/10.1148/rg.297095050
Murray, R. K. et ál. (2015). HARPER. Bioquímica ilustrada. 29a edición. McGraw Hill.
O’Reilly, M.S. et ál. (1997). Endostatin an endogenous inhibitor of angiogenesis and tumor growth. Cell. Jan 24. 88:277-285. https://doi.org/10.1016/S0092-8674(00)81848-6
Phansih, M. K. et ál. (2000). Tumoral calcinosis associated with pyrexia and systemic inflammatory response in a patient hemodialysis: successful treatment using intravenous pamidronate. Nephrol Dial Transplant. 15:1691-1693. https://doi.org/10.1093/ndt/15.10.1691
Rachnerd, T.D. & Hofbauer, K.S. (2011). Osteoporosis: now and the future. Lancet. 377:1276-1287. https://doi.org/10.1016/S0140-6736(10)62349-5
Restrepo C.A. y Manjarrés G. (2009). Controversia en relación con el uso de bifosfonatos en pacientes con enfermedad renal. Acta Med Colomb. 34:176-184.
Richards, J.B. et ál. (2008). Bone mineral density, osteoporosis and osteoporotic fractures: a genome-wide association study. Lancet. 371:1505-1512. https://doi.org/10.1016/S0140-6736(08)60599-1
Roelofs, A.J.; Thompson, K.; Gordon, S. & Rogers, M. J. (2006). Molecular Mechanisms of Action of Bisphosphonates: Current Status. Clin Cancer Res. 12: 6222-6230. https://doi.org/10.1158/1078-0432.CCR-06-0843
Romero Barco, C.M. et ál. (2012). Marcadores bioquímicos en osteoporosis. Utilidad en la práctica clínica. Reumatol. Clin. 8(3):149-152. https://doi.org/10.1016/j.reuma.2011.05.010
Rosen, L S, et ál. (2003). The long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 98:1735-1744. https://doi.org/10.1002/cncr.11701
Rowland, M. & Tozer, T.N. (2011). Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4rd. Ed. Lippincott Williams and Wilkins. Philadelphia.
Russell, R. G. & Rogers, M. J. (1999). Bisphosphonates: from the laboratory to the clinic and back again. Bone. 25: 97-106. https://doi.org/10.1016/S8756-3282(99)00116-7
Sartori, P. et ál. (2015). Osteonecrosis del maxilar inferior por bifosfonatos. Presentación de caso. Rev Argent Radiol. 79(1):40-46. https://doi.org/10.1016/j.rard.2014.11.001
Sosa Henríquez, M.; Vicente Barrero, M. y Bocanegra Pérez, S. (2011). Osteonecrosis de los maxilares: nuevas evidencias sobre su etiopatogenia. Rev Osteoporos Metab Miner. 3:5-6.
Taylor, R.C.; Cullen, S.P. & Martin, S.J. (2008). Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 9:231-241. https://doi.org/10.1007/s10495-008-0208-7
Toussaint, N.D.; Elder, G.J. & Kerr P.G. (2009). Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue. Clin J Am Soc Nephrol. 4: 221-233. https://doi.org/10.2215/CJN.02550508
Trouvin, A.P. & Goëb, V. (2010). Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clinical Interventions in Aging. 5: 345–354. https://doi.org/10.2147/CIA.S10153
Vink, A, et ál. (2007). HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis. 195(2):69-75. https://doi.org/10.1016/j.atherosclerosis.2007.05.026
Wierna, A. et ál. (2009). Osteonecrosis maxilar postextracción dentaria en pacientes bajo tratamiento con bifosfonatos: presentación de 2 casos clínicos. Rev Circ Argent Odontol. 66:14-18.
Ylitalo, R. (2000). Bisphosphonates and atherosclerosis. Gen Pharmacol. 35:287-896. https://doi.org/10.1016/S0306-3623(01)00121-5
Young, S.G. et ál. (2013). Targeting Protein Prenylation in Progeria. Sci Transl Med. 2(5):171-174. https://doi.org/10.1126/scitranslmed.3005229
Downloads
Published
Issue
Section
License
Copyright (c) 2018 José Manuel Rivera Pérez
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with Odontología Vital agree to the following terms:
- Authors retain the copyright and grant Universidad Latina de Costa Rica the right of first publication, with the work simultaneously licensed under a Creative Commons Attribution 4.0 International license (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the Odontología Vital's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
